Key PointsQuestion
What are the treatment outcomes and adverse effects of surgical interventions for patients with vitiligo?
Findings
In this systematic review and meta-analysis that included 117 unique studies and 8776 unique patients, the rates of repigmentation above 90% and above 50% after a single session of all surgical interventions were 52.69% and 81.01%, respectively.
Meaning
These findings suggest that surgical intervention can be an effective and safe option for managing refractory stable vitiligo; selection of appropriate patients in terms of disease stability and suitable surgical procedure is important.
Importance
Surgical interventions are a key part of the therapeutic arsenal, especially in refractory and stable vitiligo. Comparison of treatment outcomes between the different surgical procedures and their respective adverse effects has not been adequately studied.
Objective
To investigate the reported treatment response following different surgical modalities in patients with vitiligo.
Data Sources
A comprehensive search of the MEDLINE, Embase, Web of Science, and Cochrane Library databases from the date of database inception to April 18, 2020, was conducted. The key search terms used were vitiligo, surgery, autologous, transplantation, punch, suction blister, and graft.
Study Selection
Of 1365 studies initially identified, the full texts of 358 articles were assessed for eligibility. A total of 117 studies were identified in which punch grafting (n = 19), thin skin grafting (n = 10), suction blister grafting (n = 29), noncultured epidermal cell suspension (n = 45), follicular cell suspension (n = 9), and cultured epidermal cell suspension (n = 17) were used.
Data Extraction and Synthesis
Three reviewers independently extracted data on study design, patients, intervention characteristics, and outcomes. Random effects meta-analyses using generic inverse-variance weighting were performed.
Main Outcomes and Measures
The primary outcomes were the rates of greater than 90%, 75%, and 50% repigmentation response. These rates were calculated by dividing the number of participants in an individual study who showed the corresponding repigmentation by the total number of participants who completed the study. The secondary outcomes were the factors associated with treatment response to the surgical intervention.
Results
Among the 117 unique studies and 8776 unique patients included in the analysis, rate of repigmentation of greater than 90% for surgical interventions was 52.69% (95% CI, 46.87%-58.50%) and 45.76% (95% CI, 30.67%-60.85%) for punch grafting, 72.08% (95% CI, 54.26%-89.89%) for thin skin grafting, 61.68% (95% CI, 47.44%-75.92%) for suction blister grafting, 47.51% (95% CI, 37.00%-58.03%) for noncultured epidermal cell suspension, 36.24% (95% CI, 18.92%-53.57%) for noncultured follicular cell suspension, and 56.82% (95% CI, 48.93%-64.71%) for cultured epidermal cell suspension. The rate of repigmentation of greater than 50% after any surgical intervention was 81.01% (95% CI, 78.18%-83.84%). In meta-regression analyses, the treatment response was associated with patient age (estimated slope, −1.1418), subtype of vitiligo (estimated slope, 0.3047), and anatomical sites (estimated slope, −0.4050).
Conclusions and Relevance
The findings of this systematic review and meta-analysis suggest that surgical intervention can be an effective option for refractory stable vitiligo. An appropriate procedure should be recommended based on patient age, site and size of the lesion, and costs.
Vitiligo is a skin disease characterized by the chronic loss of functional melanocytes. The disease deeply affects quality of life in these individuals, and treatment options remain limited.1,2 Medical treatments in vitiligo include phototherapy, topical corticosteroids, topical calcineurin inhibitors, and combination therapies. However, recent systematic reviews3-5 have shown that these treatments provide only partial repigmentation in most treated individuals. Surgical interventions are an alternative therapeutic option in patients with stable vitiligo that is resistant to conventional medical approaches.6
Since thin split-thickness skin grafting was first reported to successfully repigment vitiliginous patches in 1947, various surgical methods have been developed for the treatment of vitiligo, including transplant and grafting techniques.7 However, the efficacy and safety of these surgical interventions has not recently been investigated systematically. In the present study, we performed a systematic review and meta-analysis of all relevant prospective and retrospective studies to estimate the treatment responses following each type of surgical intervention for vitiligo.
Protocol and Registration
This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline and reviewed and approved by the institutional review board of St Vincent’s Hospital, Seoul, Korea. The study was registered with PROSPERO, an international database of prospectively registered systematic reviews.8
We performed a comprehensive search using predefined search terms (eTable 1 in the Supplement) in the MEDLINE, Embase, Web of Science, and Cochrane Library databases from inception to April 18, 2020. The main search terms were autologous, melanocyte, surgery, suspension, transplantation, transplant, graft, grafting, blister, punch, thin, split thickness, and vitiligo. All prospective and retrospective studies were included with no language restriction, and the reference lists in relevant review articles were scanned manually as well. All articles identified by this search were screened independently by 3 reviewers for study eligibility and data extraction (H.J.J., R.W.L., and S.H.K.).
Study selection was based on the following inclusion criteria: (1) prospective and retrospective studies; (2) participants of all age groups with a diagnosis of vitiligo; (3) at least 1 surgical intervention group; (4) at least 10 participants in each treatment arm, regardless of the dropout rate; (5) outcomes measured based on all vitiligo lesions on the patient’s whole body or each target patch; and (6) outcomes measured according to the percentage of repigmentation. Exclusion criteria consisted of the following: (1) not a clinical study; (2) outcomes measured according to criteria other than percentage of repigmentation; (3) other intervention or combination with other intervention; (4) more than a single session of surgery; and (5) the inability to contact the corresponding authors.
Three reviewers (H.J.J., R.W.L., and S.H.K.) independently identified relevant articles by searching titles and abstracts. If the abstract did not provide enough information to determine inclusion or exclusion of the study, the reviewers performed a full-text evaluation to determine eligibility. The reviewers compared the results, and discrepancies were resolved through discussion.
Data Extraction and Outcome Measures
For the meta-analysis, the 3 independent reviewers extracted the following predefined variables: authors, country, year of publication, study type, numbers of treated patients or lesions, treatment protocols, and outcome. We performed data extraction in duplicate, and any discrepancies were resolved by consensus.
Treatment Response Following Surgical Interventions and Safety Profiles
The outcome of repigmentation was evaluated as greater than 90%, greater than 75%, and greater than 50%. The treatment response rates were calculated as the number of participants or lesions who achieved the corresponding degree of repigmentation divided by the total number of participants or lesions who completed the individual study. Patients with unstable vitiligo, piebaldism, or other types of leukoderma were excluded from the analysis, whenever possible. We investigated all reported adverse events for each surgical intervention in the included studies.
Meta-regression of Age, Vitiligo Subtype, and Body Sites
Meta-regression was performed to investigate factors associated with the achievement of greater than 90% repigmentation. Selective moderating variables, such as the type of surgical intervention, age, vitiligo subtype, and the body site were investigated for that purpose. We collected the mean age of patients, proportion of segmental vitiligo, and proportion of treated lesions on the acral and joint areas in the enrolled participants for each study, whenever this was possible.
The rates of the corresponding treatment responses of the included studies were pooled by generic inverse variance weighting and were combined using a random-effects model. In each subgroup analysis, heterogeneity was assessed using the Cochran Q test and I2 value. Influence of variables on the outcome were analyzed using meta-regression. Publication bias was evaluated using the contoured funnel plot (eFigure 1 in the Supplement). Statistical analyses were conducted using R software, version 3.6.1 (R Foundation for Statistical Computing) with the metagen and metafor packages. Two-sided P < .05 indicated significance.
We initially identified 1365 records through database searching; 656 duplicates were removed and 351 were deleted after reviewing the titles and abstracts (Figure 1). A total of 358 full-text articles were assessed for eligibility, of which 241 were excluded for the following reasons: (1) not a clinical study (n = 23); (2) less than 10 participants included (n = 61); (3) abstract only or not enough information about the methods (n = 31); (4) outcomes measured according to criteria other than percentage of repigmentation (n = 61); (5) not a single-session surgery (n = 16); (6) other intervention used with surgery (n = 7); (7) duplicated studies (n = 14); and (8) the inability to reach corresponding authors at least twice by email (n = 28). The remaining 117 studies fulfilled the inclusion criteria and were included in the final analysis.
Characteristics of Included Studies
We analyzed a total of 117 unique studies with 8776 unique patients (eTable 1 in the Supplement), including 19 studies9-27 with 1631 patients in the punch grafting group, 10 studies15,20,28-35 with 718 patients in the thin skin grafting group, 29 studies10,24,36-62 with 2652 patients in the suction blister grafting group, 45 studies21,51,56,63-104 with 2209 patients in the noncultured epidermal cell suspension (NCES) group, 9 studies75,87,93,105-110 with 185 patients in the noncultured follicular cell suspension (NCFS) group, and 17 studies56,81,111-125 with 1381 patients in the cultured epidermal cell suspension (CES) group; 11 studies included more than 1 procedure type. The median follow-up duration was 7 (range, 2-108) months. The Methodological Index for Non-randomized Studies126 criteria scoring was used to assess the methodological quality for included studies (eTable 2 in the Supplement).
Treatment Response Following Surgical Intervention and Meta-regression
Overall, the rate of repigmentation achieved by patients after 1 session of any surgical intervention included greater than 90% in 52.69% (95% CI, 46.87%-58.50%) in 106 studies with 6586 patients (I2 = 97.2%) (eFigure 2 in the Supplement); greater than 75% in 64.72% (95% CI, 59.52%-69.92%) in 100 studies with 3400 patients (I2 = 95.7%); and greater than 50% in 81.01% (95% CI, 78.18%-83.84%) in 92 studies with 5462 patients (I2 = 90.7%). Quiz Ref IDAccording to the surgical intervention type, greater than 90% repigmentation was achieved in 72.08% (95% CI, 54.26%-89.89%) of patients undergoing thin skin grafting (670 patients in 8 studies20,28-33,35), 61.68% (95% CI, 47.44%-75.92%) of patients undergoing suction blister grafting (2349 patients in 21 studies36-42,46-52,54-56,58-61), 56.82% (95% CI, 48.93%-64.71%) of patients undergoing CES (1138 patients in 14 studies56,111-123), 47.51% (95% CI, 37.00%-58.03%) of patients undergoing NCES (907 patients in 29 studies51,56,63-66,69-71,75-77,79,82,83,85,87,89,91,93-98,100-103), 45.76% (95% CI, 30.67%-60.85%) of patients undergoing punch grafting (1354 patients in 11 studies9,11-14,16,17,19,20,23,26), and 36.24% (95% CI, 18.92%-53.57%) of patients undergoing NCFS (160 patients in 8 studies75,87,93,105-107,109,110) after 1 session of each surgery (eFigure 2 in the Supplement and Table 1). In our meta-regression analysis, for greater than 90% repigmentation, the estimate of the slopes for mean age of patients was −1.1418 (P = .02); for the proportion of segmental vitiligo, 0.3047 (P = .01); and for the proportion of treated lesions on the acral and joint areas, −0.4050 (P = .002) (Figure 2).
Safety of Each Surgical Intervention
The occurrence of adverse events was reported in 56 studies. Quiz Ref IDCommon adverse events included pain, hyperpigmentation at the recipient site, and hypopigmentation at the donor site regardless of the type of the procedure. In punch grafting, cobblestone appearance, milia, and color mismatch were the most common and critical adverse events.9-13,15-18,20,22-24,26,27 In suction blister grafting, perigraft halo, variegated appearance, and color mismatch were frequently reported.10,24,36-38,40,43,45,46,48-50,54,55,57,60 Thin skin grafting was associated with graft contracture, overhanging margin, wrinkles over the graft surface, and perigraft halo.15,20,28-31,33-35 In cellular grafting techniques, pain, discomfort, and burning sensation were more commonly reported when compared with tissue grafting,84,104 which was likely owing to multiple injections of local anesthetic performed over a large area in the former. Mottled pigmentation, marginal halo, and scarring were also reported in all the evaluated surgical interventions. Koebner phenomenon at the donor site or disease progression was reported in several studies as well,9,13,36,37,40,49,54,65,96,114,115 indicating a need for carefully assessing disease stability before performing surgery (Table 2).
Surgical interventions are essential for the management of refractory stable vitiligo, which can be classified into tissue grafting and cellular grafting according to the nature of the grafts. Tissue grafting, including thin skin grafting, suction blister grafting, and punch grafting, has been traditionally performed for a long time, whereas cellular grafting has made a great advance in recent years. For many reasons, including ease of use and safety, NCES has greatly contributed to the reduced costs of surgical interventions for vitiligo, globally. A systematic review on surgical interventions for vitiligo was published in 2013,127 and the present study further includes all the articles published since then and derives the response rate for each surgical method.
In the present study, we systematically reviewed the treatment response following different types of surgical interventions for vitiligo, including punch grafting (19 studies), thin skin grafting (10 studies), suction blister grafting (29 studies), NCES (45 studies), NCFS (9 studies), and CES (17 studies). Quiz Ref IDIn meta-analysis, regardless of the type of intervention, 52.69% of the patients achieved greater than 90% repigmentation after a single surgical procedure. However, when evaluating this specific outcome according to the type of intervention, the highest response rate (for >90% repigmentation) was achieved in patients undergoing thin skin grafting (72.08%), followed by suction blister grafting (61.68%), CES (56.82%), NCES (47.51%), punch grafting (45.76%), and NCFS (36.24%).
The oldest reported surgical procedure performed in patients with vitiligo, thin skin grafting, encompasses all methods of transplanting ultrathin or thin skin grafts measuring 0.125 to 0.275 mm harvested using a manual or electronic dermatome.128 Various modifications have been added to the initially published method such as Thiersch,129 smash,130 and flit-top20 grafting. However, this technique is difficult to use on a large surface area and requires experienced skill to harvest the graft with a constant thickness.
Because thin skin grafting commonly leads to uneven pigmentation and scarring of the donor site, a surgical method to precisely harvest the epidermal graft has been attempted.131Quiz Ref ID Suction blister grafting, first described by Falabella132 in 1971, has decreased the risk of scarring of the donor site by raising subepidermal blisters with clear noninflammatory transudate and low suction pressures maintained for sufficient periods. It is safe and effective for vitiligo on junctional areas or curved areas such as lips or eyelids.133 Several studies46,58,61 reported that 87% to 90% of the lip vitiligo and 85.7% of vitiligo on the nipple and areolar showed complete repigmentation after suction blister grafting at 6 to 24 months.
Punch grafting is another well-established surgical method in vitiligo. Several motorized punch grafting devices have been put on the market in recent years, making this method more convenient and cost-effective with increased favorable outcomes.23 Moreover, repeated procedures can be easily performed in an outpatient setting. Despite the low overall treatment response following punch grafting shown in our meta-analysis, recent studies describe motorized micropunch grafting has a greatly increased response rate and reduced cobblestone appearance.23,134
Transplant of NCES is the most commonly performed cellular grafting technique for vitiligo. The procedure can treat large areas covering a ratio of donor to recipient of as much as 1:10. However, processing of the grafts is time-consuming, and the procedure itself is lengthy. In our study, greater than 90% repigmentation was achieved in 47.51%, and greater than 75% repigmentation was achieved in 63.42% after 1 session of NCES, which is slightly less than the previously reported success rate.63 Of note, treatment outcome in NCES is strongly related to the experience and skill of the surgeon and proper processing of the cell suspension. The initially reported method135 has undergone several modifications over time to improve repigmentation rates. For example, the use of hyaluronic acid instead of the patient’s serum was added to increase the viscosity and facilitate adherence of the cell suspension grafts.65 Furthermore, oral pulse betamethasone therapy started as early as 2 months after initial NCES procedure has been shown to enhance repigmentation in patients who underwent additional transplant.136
The hair follicle is an attractive reservoir, given its high density of melanocytes and melanocyte stem cells; however, NCFS was shown to be inferior to other surgical interventions in our study. Singh et al75 reported that greater than 90% repigmentation was observed in 83% of the NCES group and 65% of the NCFS group. The success rate of cellular grafting can be optimized as demonstrated in another randomized controlled study87 in which the combination of NCES and NCFS improved repigmentation rates compared with NCES alone (76% vs 57%).
Cultured epidermal cell suspension has been performed to expand the amount of autologous cell suspensions, allowing for wider graft areas. Cultured melanocytes at a density of 70 000 to 100 000 melanocytes/cm2 are transplanted to an area covering as much as 500 cm2. Hong et al116 reported that CES could provide the highest donor-to-recipient ratio to 1:60. However, melanocyte culture is time-consuming and costly and requires a laboratory specialized in cell culture and a highly stimulatory media.111 Basic fibroblast growth factor is an effective and safe media commonly used,137 but long-term safety of melanoma risk remains to be addressed.138
Quiz Ref IDIn our meta-regression analyses, successful outcome (>90% repigmentation) was associated with younger age, segmental vitiligo, and nonacral area (P < .05 for all). Therefore, selection of appropriate candidates would be a critical factor when considering the surgical intervention of vitiligo.
Phototherapy may also play an adjuvant role in surgical interventions for vitiligo by stimulating melanocyte spreading, inhibiting T lymphocytes, and suppressing the various cytokines to create a favorable environment for the transplanted melanocytes. Several studies reported narrow-band UV-B phototherapy before and after CES-accelerated repigmentation121 and adjuvant narrow-band UV-B phototherapy after NCES-enhanced repigmentation.97 In our study, subgroup analysis according to adjuvant phototherapy showed no significant difference in repigmentation rates. The large heterogeneity of these studies may limit the interpretation of the results; thus, randomized clinical trials to estimate the effect of adjuvant phototherapy are necessary.
The assessment of disease stability is critical when selecting appropriate candidates for surgical interventions in patients with vitiligo. Evaluation with digital photographs during a 12-month period in addition to a scoring system such as the Vitiligo Area Scoring Index139 or the Vitiligo European Task Force140 assessment score is recommended.141 However, many studies were performed before the publication of these recommendations, and a great heterogeneity of definition of the length of stability was observed ranging from 3 to 12 months. The most commonly used scoring system, the Vitiligo Disease Activity Score,142 could also lead to recall bias. As a result, Koebner phenomenon at the donor site after surgery was commonly reported. This reflects how the adequate assessment of disease stability would be essential when considering surgical options; therefore, test grafting or patient-reported Vitiligo Noticeability Scale scores143 could be useful options because they are quick, simple, and readily interpreted in the outpatient clinic.28
Long-term treatment outcomes are also an important aspect for patients deciding to undergo surgical treatments. Patients expect not only repigmentation but also maintenance of gained repigmentation, expectations that were validated by international e-Delphi consensus.144 However, vitiligo often recurs after successful repigmentation, and prospective studies reporting the long-term outcome in surgical interventions are lacking. Fongers et al17 reported that at least 65% repigmentation was maintained in 51% and 89% of the patients with vitiligo vulgaris and segmental vitiligo, respectively, after several sessions of punch grafting (mean follow-up, 5.2 years). Al-Mutairi et al30 reported that the thin skin grafting with adjuvant excimer laser treatment led to long-lasting repigmentation for as long as 4 years. Jin et al49 observed that repigmentation significantly decreased over time, especially starting from 2 years after epidermal grafting. Altalhab et al88 reported that 103 of 553 patients who underwent a single session of melanocyte-keratinocyte transplant (18.6%) showed a relapse after 6-year follow-up; focal and segmental vitiligo showed a significantly lower recurrence rate.
Each surgical intervention for vitiligo has advantages and disadvantages. Therefore, the appropriate procedure should be recommended based on the patient’s age, economic status, the location and extent of vitiligo, and the facilities available at the clinic. Because complete repigmentation is rarely achieved after 1 session, multiple sessions are necessary to improve treatment outcome and patient satisfaction. Lesions of large areas can first be treated by cellular grafting, followed by tissue grafting for smaller remaining areas.145
Our systematic review has limitations. First, there was considerable heterogeneity in study designs, demographic information, and protocols regarding preoperative and postoperative procedures. In particular, we observed a great heterogeneity of definition of outcome measures because the studies were published before the international consensus was reached. Repigmentation has currently reached consensus to use percentage of repigmentation quartiles, including 0 to 25%, 26% to 50%, 51% to 79%, and 80% to 100%.146 Second, limited evidence was available from randomized clinical trials or systematic reviews. Last, because the outcome of surgical interventions largely depends on the skill and experience of the clinician, actual outcomes may vary among the studies.
The findings of this systematic review and meta-analysis confirm that surgical interventions are essential for the management of refractory stable vitiligo. Maximizing treatment outcomes requires the selection of appropriate patients in terms of disease stability and suitable surgical technique. In the future, we should categorize patients for the surgical procedure that is performed. Consensus among physicians should also be reached on preoperative evaluations and postoperative assessments.
Accepted for Publication: December 19, 2020.
Published Online: February 17, 2021. doi:10.1001/jamadermatol.2020.5756
Corresponding Author: Khaled Ezzedine, MD, PhD, Department of Dermatology, Mondor Hospital, Assistance Publique–Hôpitaux de Paris, Paris Est Créteil University, F-94000 Créteil, France (khaled.ezzedine@aphp.fr).
Author Contributions: Drs Ju and Bae contributed equally to this study. Drs Ju and Bae had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Bae, Kim, Parsad, Shourick.
Acquisition, analysis, or interpretation of data: Ju, Bae, Lee, Kim, Pourang, Hamzavi, Ezzedine.
Drafting of the manuscript: Ju, Lee, Kim.
Critical revision of the manuscript for important intellectual content: Bae, Lee, Parsad, Pourang, Hamzavi, Shourick, Ezzedine.
Statistical analysis: Ju, Bae.
Administrative, technical, or material support: Ju, Bae, Lee, Pourang.
Supervision: Bae, Parsad, Hamzavi, Ezzedine.
Conflict of Interest Disclosures: Dr Hamzavi reported receiving personal fees from Avita and Arcutis Biotherapeutics and grants from Pfizer, Inc, Incyte Corp, and iTN Worldwide during the conduct of the study. No other disclosures were reported.
Funding/Support: This study was supported by grant NRF-2020R1I1A1A01074967 from the National Research Foundation of Korea (NRF), funded by the Ministry of Education.
Role of the Funder/Sponsor: The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
6.Holla
AP, Parsad
D. Vitiligo surgery: its evolution as a definite treatment in the stable vitiligo.
G Ital Dermatol Venereol. 2010;145(1):79-88.
PubMedGoogle Scholar 13.Hallaji
Z, Daneshpazhooh
M, Rezai-Khiabanloo
S. Successful treatment of vitiligo with punch graft followed by outdoor topical psoralen plus ultraviolet a radiation.
Arch Iranian Med. 2003;6(2):86-90.
Google Scholar 14.Ghorpade
A. Use of tissue glue for punch grafting in vitiligo—a preliminary report.
Indian J Dermatol Venereol Leprol. 2004;70(3):159-161.
PubMedGoogle Scholar 16.Masood
Q, Majid
I, Hassan
I, Khan
D. Miniature punch grafting in recalcitrant vitiligo.
JK Pract. 2005;12(2):81-82.
Google Scholar 17.Fongers
A, Wolkerstorfer
A, Nieuweboer-Krobotova
L, Krawczyk
P, Tóth
GG, van der Veen
JP. Long-term results of 2-mm punch grafting in patients with vitiligo vulgaris and segmental vitiligo: effect of disease activity.
Br J Dermatol. 2009;161(5):1105-1111. doi:
10.1111/j.1365-2133.2009.09367.x
PubMedGoogle ScholarCrossref 19.Linthorst Homan
MW, Spuls
PI, Nieuweboer-Krobotova
L,
et al. A randomized comparison of excimer laser versus narrow-band ultraviolet B phototherapy after punch grafting in stable vitiligo patients.
J Eur Acad Dermatol Venereol. 2012;26(6):690-695. doi:
10.1111/j.1468-3083.2011.04147.x
PubMedGoogle ScholarCrossref 21.Kumar
R, Singh
SK, Gupta
AK, Patel
PK, Chhachhi
H, Patel
RK. Comparative study of efficacy of non-cultured melanocyte transfer technique and punch grafting technique in the management of stable vitiligo.
J Evolution Med Dent Sci. 2015;4(102):16754-16758. doi:
10.14260/jemds/2015/2509
Google ScholarCrossref 24.Ezz-Eldawla
R, Abu El-Hamd
M, Saied
SM, Hassanien
SH. A comparative study between suction blistering graft, mini punch graft, and hair follicle transplant in treatment of patients with stable vitiligo.
J Dermatolog Treat. 2019;30(5):492-497. doi:
10.1080/09546634.2018.1528329
PubMedGoogle ScholarCrossref 26.Anbar
T, Abd El Raheem
T, Bassiouny
DA,
et al. Value of silicone gel in prevention of cobblestoning following punch minigrafting in vitiligo.
J Dermatolog Treat. Published online April 13, 2020.
PubMedGoogle Scholar 27.Kim
DS, Ju
HJ, Lee
HN,
et al. Skin seeding technique with 0.5-mm micropunch grafting for vitiligo irrespective of the epidermal-dermal orientation: animal and clinical studies.
J Dermatol. 2020;47(7):749-754. doi:
10.1111/1346-8138.15390
PubMedGoogle ScholarCrossref 31.Majid
I, Imran
S. Ultrathin split-thickness skin grafting followed by narrowband UVB therapy for stable vitiligo: an effective and cosmetically satisfying treatment option.
Indian J Dermatol Venereol Leprol. 2012;78(2):159-164. doi:
10.4103/0378-6323.93632
PubMedGoogle ScholarCrossref 33.Majid
I. Ultra-thin skin grafting in resistant stable vitiligo: factors affecting the treatment outcome.
Pigment Cell Melanoma Res. 2014;27(5):988.
Google Scholar 34.Sankara
RK, Rao
DS, Ramachandra
BV, Srinivasulu
G, Lakshmi
NB. A study of split thickness skin graft technique in stable acral vitiligo.
J Evolution Med Dental Sci. 2016;5(30):1581-1585. doi:
10.14260/jemds/2016/372
Google ScholarCrossref 41.Lim
JT. Repigmentation of vitiligo with autologous blister-induced epidermal grafts.
Ann Acad Med Singap. 1999;28(6):824-828.
PubMedGoogle Scholar 44.Kim
SE, Kim
JR, Kim
TH. The comparative study of the epidermal graft by suction blister between simple and complicated cases of vitiligo.
Korean J Dermatol. 2003;41(6):716-721.
Google Scholar 45.Cho
WI, Kim
JE, Seo
SJ, Hong
CK. The effect of autologous epidermal grafting in the treatment of intractable vitiligo.
Korean J Dermatol. 2005;43(4):455-461.
Google Scholar 49.Jin
Y, Xu
A, Wang
P, Song
X, Liu
X. Long-term follow-up and correlated factors of vitiligo following autologous epidermal transplantation.
Cutis. 2011;87(3):137-141.
PubMedGoogle Scholar 51.Budania
A, Parsad
D, Kanwar
AJ, Dogra
S. Comparison between autologous noncultured epidermal cell suspension and suction blister epidermal grafting in stable vitiligo: a randomized study.
Br J Dermatol. 2012;167(6):1295-1301. doi:
10.1111/bjd.12007
PubMedGoogle ScholarCrossref 56.Bao
H, Hong
W, Fu
L, Wei
X, Qian
G, Xu
A. Blister roof grafting, cultured melanocytes transplantation and non-cultured epidermal cell suspension transplantation in treating stable vitiligo: a mutual self-control study.
J Dermatolog Treat. 2015;26(6):571-574. doi:
10.3109/09546634.2015.1034068
PubMedGoogle ScholarCrossref 60.Iwanowski
T, Szlązak
P, Rustowska
A, Sokołowska-Wojdyło
M. Efficacy of suction blister epidermal grafting with concomitant phototherapy in vitiligo treatment.
Postepy Dermatol Alergol. 2018;35(6):592-598. doi:
10.5114/pdia.2017.71257
PubMedGoogle ScholarCrossref 62.Khan
R, Sharma
A, Bhushan
A, Basnet
B, Sharma
VK, Gupta
S. Relationship between α-melanocyte stimulating hormone levels and therapeutic outcome of melanocyte transplantation and phototherapy in non-segmental patients with vitiligo: a prospective study.
Australas J Dermatol. 2018;59(4):e315-e318. doi:
10.1111/ajd.12769
PubMedGoogle ScholarCrossref 63.van Geel
N, Ongenae
K, De Mil
M, Haeghen
YV, Vervaet
C, Naeyaert
JM. Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo.
Arch Dermatol. 2004;140(10):1203-1208. doi:
10.1001/archderm.140.10.1203
PubMedGoogle ScholarCrossref 65.van Geel
N, Ongenae
K, Vander Haeghen
Y, Vervaet
C, Naeyaert
JM. Subjective and objective evaluation of noncultured epidermal cellular grafting for repigmenting vitiligo.
Dermatology. 2006;213(1):23-29. doi:
10.1159/000092833
PubMedGoogle ScholarCrossref 66.Mulekar
SV, Al Issa
A, Al Eisa
A. Treatment of vitiligo on difficult-to-treat sites using autologous noncultured cellular grafting.
Dermatol Surg. 2009;35(1):66-71.
PubMedGoogle Scholar 67.Malhotra
SK, Puri
KJPS, Singh
S. Non-cultured epidermal cell suspension-a simpler solution for a complex disease vitiligo.
Pigment Cell Melanoma Res. 2010;23(3):462.
Google Scholar 68.Holla
AP, Kumar
R, Parsad
D, Kanwar
AJ, Mehta
SD. Role of wound bed nutrition in non cultured epidermal suspension transplantation in vitiligo.
Pigment Cell Melanoma Res. 2011;24(4):835.
Google Scholar 71.Sahni
K, Parsad
D, Kanwar
AJ, Mehta
SD. Autologous noncultured melanocyte transplantation for stable vitiligo: can suspending autologous melanocytes in the patients’ own serum improve repigmentation and patient satisfaction?
Dermatol Surg. 2011;37(2):176-182. doi:
10.1111/j.1524-4725.2010.01847.x
PubMedGoogle ScholarCrossref 72.Gimenez-Azcarate
A, Bernad
I, Irarrazaval
I, Lera
M, Redondo
P. Double-blind, randomized, intraindividually controlled clinical trial to evaluate the efficacy of autologous melanocyte cell transplant using amniotic membrane as a scaffold in the treatment of stable vitiligo.
J Am Acad Dermatol. 2013;68(4):AB189.
Google Scholar 73.Holla
AP. Short-duration cold trypsinization as a novel method in noncultured epidermal suspension transplantation in stable vitiligo.
Br J Dermatol. 2013;169:67-68.
Google ScholarCrossref 74.Holla
AP, Sahni
K, Kumar
R, Parsad
D, Kanwar
A, Mehta
SD. Acral vitiligo and lesions over joints treated with non-cultured epidermal cell suspension transplantation.
Clin Exp Dermatol. 2013;38(4):332-337. doi:
10.1111/ced.12040
PubMedGoogle ScholarCrossref 75.Singh
C, Parsad
D, Kanwar
AJ, Dogra
S, Kumar
R. Comparison between autologous noncultured extracted hair follicle outer root sheath cell suspension and autologous noncultured epidermal cell suspension in the treatment of stable vitiligo: a randomized study.
Br J Dermatol. 2013;169(2):287-293. doi:
10.1111/bjd.12325
PubMedGoogle ScholarCrossref 76.Bassiouny
D, El-Zawahry
BM, Esmat
S,
et al Effect of procedural-related variables on melanocytekeratinocye suspension transplantation in stable vitiligo: a clinical and immunohistochemical study.
Pigment Cell Melanoma Res. 2014;27(5):903.
Google Scholar 77.Budania
A, Khunger
N. Non cultured epidermal cell suspension for stable vitiligo from lab to dermatologists clinic: an oversimplification or a real possibility.
Pigment Cell Melanoma Res. 2014;27(5):985-986.
Google Scholar 78.Holla
AP. Combined cell suspension transplantation in stable vitiligo.
Br J Dermatol. 2014;171:69.
Google ScholarCrossref 79.Razmi
MT, Parsad
D, Kumaran
SM. Transplantation of autologous noncultured extracted hair follicle outer root sheath cell and autologus noncultured epidermal cell suspension in combination as a novel method in vitiligo surgery.
Pigment Cell Melanoma Res. 2014;27(5):903-904.
Google Scholar 80.Holla
AP. Recombinant protease for cell separation as a safer alternate to trypsin in noncultured epidermal suspension transplantation in stable vitiligo.
Br J Dermatol. 2015;173:105-106.
Google Scholar 81.Verma
G, Varkhande
SR, Kar
HK, Rani
R. Evaluation of repigmentation with cultured melanocyte transplantation (CMT) compared with non-cultured epidermal cell transplantation in vitiligo at 12th week reveals better repigmentation with CMT.
J Invest Dermatol. 2015;135(10):2533-2535. doi:
10.1038/jid.2015.178
PubMedGoogle ScholarCrossref 82.Bassiouny
D, ElZawahry
B, Esmat
S,
et al Autologous melanocyte-keratinocyte suspension in NSV: is supplementation of the suspension medium beneficial.
Pigment Cell Melanoma Res. 2017;30(5):e3-.
Google Scholar 83.El-Zawahry
BM, Esmat
S, Bassiouny
D,
et al. Effect of procedural-related variables on melanocyte-keratinocyte suspension transplantation in nonsegmental stable vitiligo: a clinical and immunocytochemical study.
Dermatol Surg. 2017;43(2):226-235. doi:
10.1097/DSS.0000000000000962
PubMedGoogle ScholarCrossref 84.Kachhawa
D, Rao
P, Kalla
G. Simplified non-cultured non-trypsinised epidermal cell graft technique followed by psoralen and ultraviolet a light therapy for stable vitiligo.
J Cutan Aesthet Surg. 2017;10(2):81-85. doi:
10.4103/JCAS.JCAS_119_16
PubMedGoogle ScholarCrossref 85.Liu
Z, Li
W, Zeng
A,
et al Is suction blister epidermal grafting a simple and reliable way to screen patients with large area vitiligo for ReCell treatment?
J Invest Dermatol. 2017;137(10):S197. doi:
10.1016/j.jid.2017.07.124
Google ScholarCrossref 86.Mutalik
S, Shah
S, Sidwadkar
V, Khoja
M. Efficacy of cyclosporine after autologous noncultured melanocyte transplantation in localized stable vitiligo—a pilot, open label, comparative study.
Dermatol Surg. 2017;43(11):1339-1347. doi:
10.1097/DSS.0000000000001190
PubMedGoogle ScholarCrossref 87.Razmi T
M, Kumar
R, Rani
S, Kumaran
SM, Tanwar
S, Parsad
D. Combination of follicular and epidermal cell suspension as a novel surgical approach in difficult-to-treat vitiligo: a randomized clinical trial.
JAMA Dermatol. 2018;154(3):301-308. doi:
10.1001/jamadermatol.2017.5795
PubMedGoogle ScholarCrossref 88.Altalhab
S, AlJasser
MI, Mulekar
SV,
et al. Six-year follow-up of vitiligo patients successfully treated with autologous non-cultured melanocyte-keratinocyte transplantation.
J Eur Acad Dermatol Venereol. 2019;33(6):1172-1176. doi:
10.1111/jdv.15411
PubMedGoogle ScholarCrossref 89.Awasti
S, Vinay
K, Thakur
V,
et al. Comparison of efficacy of cold trypsinization versus warm trypsinization in preparation of autologous non-cultured epidermal cell suspension for treatment of stable vitiligo.
J Eur Acad Dermatol Venereol. 2019;33(6):e237-e239. doi:
10.1111/jdv.15502
PubMedGoogle ScholarCrossref 90.Chuah
SY, Thng
STG. The role of in vivo reflectance confocal microscopy in assessing the stability of vitiligo vulgaris prior to cellular grafting.
Skin Res Technol. 2019;25(2):245-247. doi:
10.1111/srt.12638
PubMedGoogle ScholarCrossref 92.Gupta
S, Relhan
V, Garg
VK, Sahoo
B. Autologous noncultured melanocyte-keratinocyte transplantation in stable vitiligo: a randomized comparative study of recipient site preparation by two techniques.
Indian J Dermatol Venereol Leprol. 2019;85(1):32-38.
PubMedGoogle ScholarCrossref 93.Hamza
AM, Hussein
TM, Shakshouk
HAR. Noncultured extracted hair follicle outer root sheath cell suspension versus noncultured epidermal cell suspension in the treatment of stable vitiligo.
J Cutan Aesthet Surg. 2019;12(2):105-111. doi:
10.4103/JCAS.JCAS_136_18
PubMedGoogle ScholarCrossref 95.Mrigpuri
S, Razmi T
M, Sendhil Kumaran
M, Vinay
K, Srivastava
N, Parsad
D. Four compartment method as an efficacious and simplified technique for autologous non-cultured epidermal cell suspension preparation in vitiligo surgery: a randomized, active-controlled study.
J Eur Acad Dermatol Venereol. 2019;33(1):185-190. doi:
10.1111/jdv.15234
PubMedGoogle ScholarCrossref 96.Parambath
N, Sharma
VK, Parihar
AS, Sahni
K, Gupta
S. Use of platelet-rich plasma to suspend noncultured epidermal cell suspension improves repigmentation after autologous transplantation in stable vitiligo: a double-blind randomized controlled trial.
Int J Dermatol. 2019;58(4):472-476. doi:
10.1111/ijd.14286
PubMedGoogle ScholarCrossref 97.Tawfik
YM, Abd Elazim
NE, Abdel-Motaleb
AA, Mohammed
RAA, Tohamy
AMA. The effect of NB-UVB on noncultured melanocyte and keratinocyte transplantation in treatment of generalized vitiligo using two different donor-to-recipient ratios.
J Cosmet Dermatol. 2019;18(2):638-646. doi:
10.1111/jocd.12759
PubMedGoogle ScholarCrossref 98.Thakur
V, Kumar
S, Kumaran
MS, Kaushik
H, Srivastava
N, Parsad
D. Efficacy of transplantation of combination of noncultured dermal and epidermal cell suspension vs epidermal cell suspension alone in vitiligo: a randomized clinical trial.
JAMA Dermatol. 2019;155(2):204-210. doi:
10.1001/jamadermatol.2018.4919
PubMedGoogle ScholarCrossref 100.Vachiramon
V, Triyangkulsri
K, Saengwimol
D, Chanprapaph
K. Outcome of repeated use of donor site for noncultured epidermal cellular grafting in stable vitiligo: a retrospective study.
Biomed Res Int. 2019;2019:7623607. doi:
10.1155/2019/7623607
PubMedGoogle Scholar 101.Anbar
TS, El-Ammawi
TS, Mohammed
SS, Abdel-Rahman
AT. Noncultured epidermal suspensions obtained from partial-thickness epidermal cuts and suction blister roofs for vitiligo treatment: a prospective comparative study.
J Cosmet Dermatol. Published online January 30, 2020. doi:
10.1111/jocd.13312
PubMedGoogle Scholar 102.Esmat
S, Bassiouny
D, Saleh
MA,
et al. Studying the effect of adding growth factors to the autologous melanocyte keratinocyte suspension in segmental vitiligo.
Dermatol Ther. 2020;33(3):e13368. doi:
10.1111/dth.13368
PubMedGoogle Scholar 103.Kumar
S, Vinay
K, Parsad
D,
et al. Comparison of recipient-site preparation by electrofulguration-assisted manual dermabrasion versus conventional manual dermabrasion in non-cultured epidermal cell suspension procedure for stable vitiligo: an open-label comparison study.
J Eur Acad Dermatol Venereol. 2020;34(7):e337-e339. doi:
10.1111/jdv.16313
PubMedGoogle ScholarCrossref 104.Rasheed
HM, Esmat
SM, Hegazy
RA,
et al. Effect of different methods of trypsinization on cell viability and clinical outcome in vitiligo patients undergoing noncultured epidermal cellular suspension.
Dermatol Surg. 2020;46(10):1307-1314. doi:
10.1097/DSS.0000000000002329
PubMedGoogle ScholarCrossref 106.Vinay
K, Dogra
S, Parsad
D,
et al. Clinical and treatment characteristics determining therapeutic outcome in patients undergoing autologous non-cultured outer root sheath hair follicle cell suspension for treatment of stable vitiligo.
J Eur Acad Dermatol Venereol. 2015;29(1):31-37. doi:
10.1111/jdv.12426
PubMedGoogle ScholarCrossref 108.Kumar
P, Bhari
N, Tembhre
MK,
et al. Study of efficacy and safety of noncultured, extracted follicular outer root sheath cell suspension transplantation in the management of stable vitiligo.
Int J Dermatol. 2018;57(2):245-249. doi:
10.1111/ijd.13759
PubMedGoogle ScholarCrossref 110.Thakur
DS, Kumar
S, Kumaran
MS, Srivastava
N, Parsad
D. Comparison of follicular unit extraction vs. plucking of hair follicles as technique of harvesting hair follicles in non-cultured hair follicular cell suspension in vitiligo.
J Eur Acad Dermatol Venereol. 2020;34(1):e34-e36. doi:
10.1111/jdv.15888
PubMedGoogle ScholarCrossref 117.Ghosh
D, Kuchroo
P, Viswanathan
C,
et al. Efficacy and safety of autologous cultured melanocytes delivered on poly (DL-lactic acid) film: a prospective, open-label, randomized, multicenter study.
Dermatol Surg. 2012;38(12):1981-1990. doi:
10.1111/dsu.12000
PubMedGoogle ScholarCrossref 118.Wei
XD, Fu
LF, Hong
WS, Qian
GP, Xu
AE. Transplantation of autologous melanocytes for the treatment of vitiligo in children: a retrospective analysis of 124 cases.
J Dermatol. 2012;39:221-222.
Google Scholar 119.Zhou
MN, Zhang
ZQ, Wu
JL,
et al. Dermal mesenchymal stem cells (DMSCs) inhibit skin-homing CD8
+ T cell activity, a determining factor of vitiligo patients’ autologous melanocytes transplantation efficiency.
PLoS One. 2013;8(4):e60254. doi:
10.1371/journal.pone.0060254
PubMedGoogle Scholar 120.Li
J, Xu
J, Fu
W, Wu
W, Chen
S, Uyama
T. Confocal laser scanning microscope is a valuable method to evaluate effectiveness of autologous cultured epidermal sheet for the treatment of stable vitiligo.
J Dermatol. 2014;41:102.
Google ScholarCrossref 121.Zhang
DM, Hong
WS, Fu
LF, Wei
XD, Xu
AE. A randomized controlled study of the effects of different modalities of narrow-band ultraviolet B therapy on the outcome of cultured autologous melanocytes transplantation in treating vitiligo.
Dermatol Surg. 2014;40(4):420-426. doi:
10.1111/dsu.12444
PubMedGoogle ScholarCrossref 122.Wu
XG, Hong
WS, Xu
A. GM-CSF: a possible prognostic serum biomarker of vitiligo patients’ considered for transplantation treatment with cultured autologous melanocytes: a pilot study.
J Eur Acad Dermatol Venereol. 2016;30(8):1409-1411. doi:
10.1111/jdv.13256
PubMedGoogle ScholarCrossref 128.Sonthalia
S, Kachhawa
D. Jodhpur Technique. StatPearls Publishing LLC; 2020.
134.Bae
JM, Kim
J, Kim
DS. Skin seeding technique using 0.8-mm motorized punch for refractory vitiligo.
Pigment Cell Melanoma Res. 2017;30(5):e130-e131.
Google Scholar 136.Mulekar
SV. Stable vitiligo treated by a combination of low-dose oral pulse betamethasone and autologous, noncultured melanocyte-keratinocyte cell transplantation.
Dermatol Surg. 2006;32(4):536-541.
PubMedGoogle Scholar 139.Hamzavi
I, Jain
H, McLean
D, Shapiro
J, Zeng
H, Lui
H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index.
Arch Dermatol. 2004;140(6):677-683. doi:
10.1001/archderm.140.6.677
PubMedGoogle ScholarCrossref 141.Ezzedine
K, Lim
HW, Suzuki
T,
et al; Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference.
Pigment Cell Melanoma Res. 2012;25(3):E1-E13. doi:
10.1111/j.1755-148X.2012.00997.x
PubMedGoogle ScholarCrossref 143.Batchelor
JM, Tan
W, Tour
S, Yong
A, Montgomery
AA, Thomas
KS. Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success.
Br J Dermatol. 2016;174(2):386-394. doi:
10.1111/bjd.14208
PubMedGoogle ScholarCrossref 144.Eleftheriadou
V, Thomas
K, van Geel
N,
et al; Vitiligo Global Issues Consensus Group. Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus.
Pigment Cell Melanoma Res. 2015;28(3):363-369. doi:
10.1111/pcmr.12354
PubMedGoogle ScholarCrossref 146.Eleftheriadou
V, Hamzavi
I, Pandya
AG,
et al. International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation.
Br J Dermatol. 2019;180(3):574-579. doi:
10.1111/bjd.17013
PubMedGoogle ScholarCrossref